FdaApplication
NDA 220910
Identifiers
- fda_app_no: NDA220910
Properties
| Property | Value |
|---|---|
| applicant_name | REVOLUTION MEDICINES |
| application_type | NDA |
| approval_date | 2026-08-26 |
Revenue by product
RASONQUE
| Period | Revenue |
|---|---|
| Q4 2024 | $0.0M† |
| Q3 2024 | $0.0M† |
| Q2 2024 | $0.0M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.7M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $3.8M† |
| Q1 2023 | $7.0M† |
| Q4 2022 | $15.3M† |
| Q3 2022 | $3.4M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RASONQUE | DARAXONRASIB | 100MG | TABLET;ORAL |
| RASONQUE | DARAXONRASIB | 150MG | TABLET;ORAL |
2 products